What Xilin Treats: Main Uses and Benefits

Xilin is relevant across therapeutic areas involving symptoms of bacterial infection and symptoms of ocular discomfort.

This antibiotic formulation is used to address certain infections caused by bacteria, including conditions presenting with systemic or localized discomfort. Its application is relevant across domains where additional symptomatic support is needed. In the context of bacterial illness, Xilin helps address symptoms that create noticeable physiological strain, such as fever and localized physical discomfort, that may become intense or disruptive. The medication is commonly used across conditions presenting with acute episodes, where short-term symptomatic assistance is appropriate.

Xilin is also applied to conditions involving episodic or fluctuating manifestations of ocular irritation and dryness, such as burning, grittiness, and temporary discomfort. This application helps manage symptoms that interfere with daily functioning and may contribute to improved day-to-day comfort during symptomatic periods.

---

“The primary goal is to provide supportive relief during symptomatic periods, helping patients cope more steadily with difficult episodes.”

Quick Fact: Relief for Symptomatic Discomfort

This medication is applied in scenarios where additional management of discomfort is required, offering symptomatic relief that helps patients cope more steadily with symptom fluctuations.

Regulatory References

1. Cefixime: MedlinePlus Drug Information

Eligibility for Xilin (Clarithromycin) — Official Regulatory Information

Official regulatory documents define the populations permitted to use Xilin and those for whom use is strictly prohibited or restricted.

Category	Eligibility Rule
Adult Use	Permitted for use in adult patients 18 years of age and older.
Pediatric Use	Approved for children 6 months of age and older for general infections; use is not established in infants under 6 months.
Absolute Contraindications	Prohibited for patients with a known macrolide antibiotic allergy, a history of QT prolongation or ventricular arrhythmias, or a history of cholestatic jaundice associated with prior clarithromycin use.
Severe Organ Dysfunction	Use is strictly limited or contraindicated in cases of severe renal impairment (creatinine clearance < 30 mL/min) and severe hepatic failure. Caution is required in patients with pre-existing hepatic disease.
Pregnancy Status	Not advised for use during pregnancy, especially in the first trimester, unless the benefit clearly outweighs the potential risks to the fetus.
Comorbidity Caution	Use requires caution and monitoring in patients with conditions like Coronary Artery Disease or Myasthenia Gravis.

Interactions with other medicines and products

The interaction profile of Xilin (Clarithromycin) is defined by its role as a strong inhibitor of the CYP3A4 enzyme and an inhibitor of P-glycoprotein ( P-gp), which leads to reduced clearance and increased systemic exposure of co-administered drugs metabolized by these pathways.

---

Absolute Co-administration Prohibitions

Several combinations are strictly contraindicated by regulatory authorities due to the high risk of serious toxicity or adverse events. These prohibitions include:

• Specific Statins: Lovastatin and Simvastatin, due to the increased risk of severe myopathy, including rhabdomyolysis.
• Ergot Alkaloids: Ergotamine and Dihydroergotamine, due to the potential for acute ergot toxicity, such as vasospasm.
• QT-Prolonging Agents: Pimozide, Astemizole, Cisapride, and Terfenadine, due to the risk of serious cardiac arrhythmias.

---

Exposure Modification and Monitoring

The resulting CYP3A4 inhibition requires monitoring when Xilin is co-administered with other clinically significant drugs. Clarithromycin increases the plasma concentrations of drugs such as Digoxin, Tacrolimus, Sildenafil, and Oral Anticoagulants, often necessitating therapeutic monitoring or dose adjustments of the interacting medicine. Furthermore, the combination with Colchicine is specifically contraindicated in patients with existing renal or hepatic impairment, reflecting a population-dependent constraint. For immediate-release tablets, food consumption slightly increases the peak plasma concentration ( Cmax).

How Xilin Works

Targeted Inhibition of Bacterial Protein Synthesis

Xilin's core mechanism involves the action of its active ingredient, Clarithromycin, as an inhibitor of bacterial protein synthesis. The molecule achieves this by reversibly binding to the 50S ribosomal subunit within the bacterial cell, specifically targeting the 23S ribosomal RNA at the entry of the peptide exit tunnel. This binding physically blocks the movement of the nascent peptide chain, immediately halting the bacterium's ability to create the essential proteins required for growth and division.

Mechanistic Cascade and Functional Consequence

The resulting mechanistic cascade leads directly to a bacteriostatic effect—meaning the proliferation and growth of susceptible bacteria are suppressed. This limitation of the microbial burden within the host environment is the key physiological adjustment, as it facilitates the host's physiological response to the suppressed microbial population. This suppression is sustained by the complementary action of the active metabolite, 14-hydroxyclarithromycin, which acts similarly on the same ribosomal target.

Mechanisms of Resistance and Mechanistic Limitations

The drug's mechanism can be limited by microbial defense systems. For instance, some bacteria express efflux pumps that actively expel the macrolide from the cell, lowering the concentration at the ribosomal target. Furthermore, the presence of specific resistance genes, such as those that mediate ribosomal methylation, can chemically alter the 23S rRNA binding site, physically preventing Clarithromycin from docking and rendering the entire inhibitory mechanism inert.

The administration of Xilin (Clarithromycin) is characterized by the formulation, dose, and intake conditions specific to the medication. The medicine is available for oral use as immediate-release (IR) tablets, extended-release (XL) tablets, and an oral suspension, as well as a powder for intravenous (IV) infusion.

Standardized Usage and Dosing

Parameter	Standard Parameter
Common Route	Oral (tablet or suspension)
Frequency	Twice Daily (q12h) for IR forms; Once Daily (q24h) for XL tablets
Typical Dose	250 mg or 500 mg twice daily for adults
Duration	Generally 6 to 14 days, depending on the specific use

Administration Conditions and Adjustments

Specific instructions define how the drug is administered. Extended-release tablets are taken with food and swallowed whole; they are not to be crushed or broken. In contrast, the immediate-release tablets and suspension may be taken without regard to meals. The oral suspension requires shaking well before each dose is measured.

Dose modification is utilized for certain populations. For patients with severe renal impairment (creatinine clearance < 30 mL/min), the total daily dose is typically reduced by one-half. Pediatric dosing is based on body weight, commonly 7.5 mg/kg twice daily. If a dose is missed, it is taken when remembered, but a double dose is not taken. The IV form is restricted to a slow, 60-minute infusion when oral administration is not possible.

Research Evidence / Overview of Studies for Xilin (Clarithromycin)

---

Evidence for Use in Respiratory Tract Infections

Research on Xilin (Clarithromycin) has primarily focused on its use in common infections of the respiratory tract. The evidence base includes numerous Randomized Controlled Trials (RCTs), which were designed to compare Clarithromycin with other treatments. These studies were used to examine how measurements related to systemic or functional status changed in both adults and children across various respiratory conditions, such as pneumonia and bronchitis. Studies monitored how symptoms evolved in the observed populations, specifically measuring rates of clinical success (resolution of signs like fever, cough, and breathing difficulty) and bacteriological clearance (the removal of the targeted germ).

What remains uncertain is the current real-world effectiveness in light of rising macrolide resistance. The scientific literature indicates that findings were mixed across different geographic regions, as the susceptibility of bacteria to the medicine has changed over time. Furthermore, follow-up durations were limited in many pivotal studies, meaning there is limited information for long-term outcomes after addressing the signs of acute infection period has passed.

---

Evidence for Use in Combination Therapy for H. pylori

Xilin was studied for the clearance of the bacterium Helicobacter pylori, which is often associated with peptic ulcer disease. This research primarily involved RCTs designed to evaluate combination therapies, where Clarithromycin was evaluated in specific combination regimens alongside other medicines. The studies monitored and reported success rates in achieving microbiological clearance, confirmed by non-invasive tests four weeks or more after the completion of the treatment course. Findings indicate patterns related to the reported rates of H. pylori clearance, which varied based on the specific regimen used.

---

Evidence Gaps and Research Uncertainty

The evidence landscape highlights several areas of uncertainty where information remains limited. A primary concern is the global and ongoing issue of antimicrobial resistance, which may reduce the effectiveness of Clarithromycin in some settings, creating uncertainty for future outcomes. Furthermore, for most indications, the follow-up durations were limited, meaning long-term effects on the body's microbiome or sustained infection control are not fully established. Finally, while many studies exist, comparative evidence directly assessing Xilin with newer antibiotics in a current resistance environment remains limited.

Key Studies & References

1. Management of community-acquired pneumonia in infants and children older than 3 months of age (NICE Guideline NG138)

Common questions about Xilin (FAQ)

---

Q: How long does Xilin stay in your system after your last dose?

Studies and official information indicate that the active ingredient, clarithromycin, generally has an elimination half-life that ranges from approximately 3 to 7 hours. This half-life describes the time required for half of the medicine to be eliminated from the body, based on official pharmacokinetic data. These measurements are used to understand the duration of the medicine's systemic presence.

---

Q: Does Xilin have any effect on birth control pills?

Regulatory documents mention that Xilin (Clarithromycin) has the potential to interact with other medicines, including hormonal contraceptives, because it can affect certain liver enzymes. Because of this potential interaction, individuals may wish to discuss the efficacy of their contraceptive method with a healthcare professional during treatment.

---

Q: What specific infections is Xilin (Clarithromycin) approved to treat?

According to the official product information, Clarithromycin is approved for treating infections caused by susceptible germs. These include upper and lower respiratory tract infections (like bronchitis and pneumonia), skin and skin structure infections, and is also used as part of a combination regimen for the eradication of the bacterium H. pylori.

---

Q: How long does it take for Xilin to start working?

Official information indicates that Xilin is rapidly absorbed after taking an oral dose, with the highest concentration in the bloodstream typically reached within 2 to 3 hours. The medicine's plasma concentration is generally sustained by regular intake, with steady-state levels typically achieved within 3 days of regular dosing.

---

Q: What is the difference between the IR and XL tablets, other than frequency?

The key difference is in how the tablets are taken. The extended-release (XL) tablets are designed to be taken once daily, and they must be swallowed whole with food as required for controlled absorption. The immediate-release (IR) tablets are typically taken twice daily and can be taken without regard to meals.

---

Q: What are the signs of a serious allergic reaction to Xilin?

Official regulatory documents highlight the potential for serious adverse reactions, which include severe cutaneous (skin) reactions. These can include conditions like Stevens-Johnson syndrome and other hypersensitivity reactions. Official labeling emphasizes that any sign of a severe reaction should be promptly addressed by a healthcare professional.

---

Q: Is Xilin used for treating sinus infections?

Yes, official regulatory documents state that Clarithromycin is approved for the treatment of acute bacterial sinusitis caused by susceptible organisms. The official documentation confirms that Clarithromycin is approved for acute bacterial sinusitis caused by susceptible organisms.

How to Store and Dispose of Xilin (Clarithromycin)

Official labeling defines strict storage requirements for Xilin to maintain its stability and effectiveness.

Storage Conditions

Dosage Form	Required Storage Temperature
Tablets	Controlled room temperature, generally 20 C to 25 C.
Oral Suspension (Prepared)	Room temperature, do not refrigerate or freeze.

The medication must be stored in its original, tightly closed container and protected from light, excess heat, and moisture. It must always be kept out of the sight and reach of children, with safety caps securely locked.

Stability and Disposal

The prepared liquid suspension has an in-use stability limit and must be discarded after 14 days from the date it was mixed. Unused or expired medication should not be flushed down the toilet or poured down a drain, but disposed of by following specific guidance from a healthcare professional or local authorized drug take-back programs.